1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Primary	_	_	JJ	_	_	_	_	_
2	liver	_	_	NN	_	_	_	_	_
3	cancer	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	sixth	_	_	JJ	_	_	_	_	_
7	most	_	_	RBS	_	_	_	_	_
8	prevalent	_	_	JJ	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	second	_	_	JJ	_	_	_	_	_
13	leading	_	_	VBG	_	_	_	_	_
14	cause	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	mortality	_	_	NN	_	_	_	_	_
18	worldwide	_	_	RB	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	common	_	_	JJ	_	_	_	_	_
4	primary	_	_	JJ	_	_	_	_	_
5	liver	_	_	NN	_	_	_	_	_
6	cancer	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	hepatocellular	_	_	JJ	_	_	_	_	_
9	carcinoma	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	HCC	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	accounts	_	_	VBZ	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	>85	_	_	CD	_	_	_	_	_
18	%	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	all	_	_	DT	_	_	_	_	_
21	cases	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	HCC	_	_	NNP	_	_	_	_	_
2	predominantly	_	_	RB	_	_	_	_	_
3	arises	_	_	VBZ	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	setting	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	cirrhosis	_	_	NN	_	_	_	_	_
9	associated	_	_	VBN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	hepatitis	_	_	NN	_	_	_	_	_
12	B	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	C	_	_	NNP	_	_	_	_	_
15	virus	_	_	NN	_	_	_	_	_
16	infections	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	alcohol	_	_	NN	_	_	_	_	_
19	abuse	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	non-alcoholic	_	_	JJ	_	_	_	_	_
22	steatohepatitis	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	metabolic	_	_	JJ	_	_	_	_	_
25	diseases	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Early-stage	_	_	JJ	_	_	_	_	_
2	HCC	_	_	NN	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	often	_	_	RB	_	_	_	_	_
6	subjected	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	surgical	_	_	JJ	_	_	_	_	_
9	resection	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	liver	_	_	NN	_	_	_	_	_
12	transplantation	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	5-year	_	_	JJ	_	_	_	_	_
4	recurrence	_	_	NN	_	_	_	_	_
5	rates	_	_	NNS	_	_	_	_	_
6	after	_	_	IN	_	_	_	_	_
7	resection	_	_	NN	_	_	_	_	_
8	reach	_	_	VBP	_	_	_	_	_
9	>70	_	_	CD	_	_	_	_	_
10	%	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	efficiency	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	transplantation	_	_	NN	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	limited	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	organ	_	_	NN	_	_	_	_	_
20	shortage	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	technical	_	_	JJ	_	_	_	_	_
23	issues	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	local	_	_	JJ	_	_	_	_	_
3	ablation	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	transarterial	_	_	JJ	_	_	_	_	_
6	chemoembolization	_	_	NN	_	_	_	_	_
7	respectively	_	_	RB	_	_	_	_	_
8	confer	_	_	VBP	_	_	_	_	_
9	5-year	_	_	JJ	_	_	_	_	_
10	survival	_	_	NN	_	_	_	_	_
11	rates	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	50	_	_	CD	_	_	_	_	_
14	â€“	_	_	TO	_	_	_	_	_
15	70	_	_	CD	_	_	_	_	_
16	%	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	survival	_	_	JJ	_	_	_	_	_
19	benefit	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	>6	_	_	CD	_	_	_	_	_
22	months	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	they	_	_	PRP	_	_	_	_	_
25	are	_	_	VBP	_	_	_	_	_
26	confined	_	_	VBN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	patients	_	_	NNS	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	single	_	_	JJ	_	_	_	_	_
31	tumors	_	_	NNS	_	_	_	_	_
32	or	_	_	CC	_	_	_	_	_
33	multinodular	_	_	JJ	_	_	_	_	_
34	tumors	_	_	NNS	_	_	_	_	_
35	with	_	_	IN	_	_	_	_	_
36	good	_	_	JJ	_	_	_	_	_
37	liver	_	_	NN	_	_	_	_	_
38	reserve	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Chemotherapy	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	routinely	_	_	RB	_	_	_	_	_
5	used	_	_	VBN	_	_	_	_	_
6	due	_	_	JJ	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	chemoresistant	_	_	JJ	_	_	_	_	_
10	character	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	HCC	_	_	NNP	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	advanced	_	_	JJ	_	_	_	_	_
3	HCC	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	sorafenib	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	multi-tyrosine	_	_	JJ	_	_	_	_	_
9	kinase	_	_	NN	_	_	_	_	_
10	inhibitor	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	MTKI	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	has	_	_	VBZ	_	_	_	_	_
16	been	_	_	VBN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	only	_	_	JJ	_	_	_	_	_
19	approved	_	_	VBN	_	_	_	_	_
20	systemic	_	_	JJ	_	_	_	_	_
21	first-line	_	_	JJ	_	_	_	_	_
22	agent	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	over	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	decade	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	until	_	_	IN	_	_	_	_	_
29	lenvatinib	_	_	NNP	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	another	_	_	DT	_	_	_	_	_
32	MTKI	_	_	NNP	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	recently	_	_	RB	_	_	_	_	_
35	came	_	_	VBD	_	_	_	_	_
36	into	_	_	IN	_	_	_	_	_
37	play	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Yet	_	_	CC	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	their	_	_	PRP$	_	_	_	_	_
4	clinical	_	_	JJ	_	_	_	_	_
5	efficacy	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	suboptimal	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	only	_	_	RB	_	_	_	_	_
11	~3	_	_	CD	_	_	_	_	_
12	months	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	prolonged	_	_	VBN	_	_	_	_	_
15	survival	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Second-line	_	_	JJ	_	_	_	_	_
2	treatments	_	_	NNS	_	_	_	_	_
3	include	_	_	VBP	_	_	_	_	_
4	regorafenib	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	cabozantinib	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	MTKIs	_	_	NNP	_	_	_	_	_
10	;	_	_	:	_	_	_	_	_
11	nivolumab	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	pembrolizumab	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	immune	_	_	JJ	_	_	_	_	_
16	checkpoint	_	_	NN	_	_	_	_	_
17	inhibitors	_	_	NNS	_	_	_	_	_
18	targeting	_	_	VBG	_	_	_	_	_
19	programmed	_	_	VBN	_	_	_	_	_
20	death-1	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	PD-1	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	;	_	_	:	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	ramucirumab	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	first	_	_	JJ	_	_	_	_	_
30	biomarker-driven	_	_	JJ	_	_	_	_	_
31	therapeutics	_	_	NNS	_	_	_	_	_
32	approved	_	_	VBN	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	HCC	_	_	NN	_	_	_	_	_
35	that	_	_	WDT	_	_	_	_	_
36	targets	_	_	VBZ	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	angiogenic	_	_	JJ	_	_	_	_	_
39	vascular	_	_	JJ	_	_	_	_	_
40	endothelial	_	_	JJ	_	_	_	_	_
41	growth	_	_	NN	_	_	_	_	_
42	factor	_	_	NN	_	_	_	_	_
43	receptor	_	_	NN	_	_	_	_	_
44	(	_	_	-LRB-	_	_	_	_	_
45	VEGFR	_	_	NN	_	_	_	_	_
46	)	_	_	-RRB-	_	_	_	_	_
47	,	_	_	,	_	_	_	_	_
48	all	_	_	DT	_	_	_	_	_
49	of	_	_	IN	_	_	_	_	_
50	which	_	_	WDT	_	_	_	_	_
51	have	_	_	VBP	_	_	_	_	_
52	not	_	_	RB	_	_	_	_	_
53	been	_	_	VBN	_	_	_	_	_
54	established	_	_	VBN	_	_	_	_	_
55	until	_	_	IN	_	_	_	_	_
56	the	_	_	DT	_	_	_	_	_
57	past	_	_	JJ	_	_	_	_	_
58	few	_	_	JJ	_	_	_	_	_
59	years	_	_	NNS	_	_	_	_	_
60	and	_	_	CC	_	_	_	_	_
61	require	_	_	VB	_	_	_	_	_
62	further	_	_	JJR	_	_	_	_	_
63	investigations	_	_	NNS	_	_	_	_	_
64	.	_	_	.	_	_	_	_	_


1	So	_	_	RB	_	_	_	_	_
2	far	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	treatment	_	_	NN	_	_	_	_	_
5	outcomes	_	_	NNS	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	HCC	_	_	NNP	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	far	_	_	RB	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	satisfactory	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	5-year	_	_	JJ	_	_	_	_	_
16	survival	_	_	NN	_	_	_	_	_
17	rate	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	only	_	_	RB	_	_	_	_	_
20	~18	_	_	CD	_	_	_	_	_
21	%	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Evidently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	urgent	_	_	JJ	_	_	_	_	_
7	need	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	develop	_	_	VB	_	_	_	_	_
10	more	_	_	RBR	_	_	_	_	_
11	effective	_	_	JJ	_	_	_	_	_
12	therapeutic	_	_	JJ	_	_	_	_	_
13	strategies	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	HCC	_	_	NNP	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Signal	_	_	NN	_	_	_	_	_
2	transducer	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	activator	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	transcription	_	_	NN	_	_	_	_	_
7	3	_	_	CD	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	STAT3	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	recently	_	_	RB	_	_	_	_	_
13	emerged	_	_	VBN	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	potential	_	_	JJ	_	_	_	_	_
17	therapeutic	_	_	JJ	_	_	_	_	_
18	target	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	HCC	_	_	NNP	_	_	_	_	_
21	due	_	_	JJ	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	its	_	_	PRP$	_	_	_	_	_
24	crucial	_	_	JJ	_	_	_	_	_
25	roles	_	_	NNS	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	oncogenesis	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	STAT3	_	_	NNP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	initially	_	_	RB	_	_	_	_	_
4	determined	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	control	_	_	VB	_	_	_	_	_
7	acute-phase	_	_	JJ	_	_	_	_	_
8	genes	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	response	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	interleukin-6	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	IL-6	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	epidermal	_	_	JJ	_	_	_	_	_
18	growth	_	_	NN	_	_	_	_	_
19	factor	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	EGF	_	_	NNP	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	during	_	_	IN	_	_	_	_	_
24	inflammation	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	belongs	_	_	VBZ	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	STAT	_	_	NNP	_	_	_	_	_
6	family	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	cytoplasmic	_	_	JJ	_	_	_	_	_
9	transcription	_	_	NN	_	_	_	_	_
10	factors	_	_	NNS	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	mediate	_	_	VBP	_	_	_	_	_
13	signal	_	_	NN	_	_	_	_	_
14	transduction	_	_	NN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	plasma	_	_	NN	_	_	_	_	_
18	membrane	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	nucleus	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	various	_	_	JJ	_	_	_	_	_
24	cellular	_	_	JJ	_	_	_	_	_
25	activities	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	STAT	_	_	NNP	_	_	_	_	_
3	family	_	_	NN	_	_	_	_	_
4	comprises	_	_	VBZ	_	_	_	_	_
5	seven	_	_	CD	_	_	_	_	_
6	members	_	_	NNS	_	_	_	_	_
7	:	_	_	:	_	_	_	_	_
8	STAT1	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	2	_	_	CD	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	3	_	_	CD	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	4	_	_	CD	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	5a	_	_	CD	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	5b	_	_	CD	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	6	_	_	CD	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Each	_	_	DT	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	them	_	_	PRP	_	_	_	_	_
4	consists	_	_	VBZ	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	(	_	_	-LRB-	_	_	_	_	_
7	i	_	_	CD	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	N-terminal	_	_	JJ	_	_	_	_	_
11	domain	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	oligomerization	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	ii	_	_	CD	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	coiled-coil	_	_	JJ	_	_	_	_	_
20	domain	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	interaction	_	_	NN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	regulatory	_	_	JJ	_	_	_	_	_
25	proteins	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	iii	_	_	CD	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	DNA-binding	_	_	NN	_	_	_	_	_
32	domain	_	_	NN	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	recognition	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	specific	_	_	JJ	_	_	_	_	_
37	DNA	_	_	NN	_	_	_	_	_
38	sequences	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	iv	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	a	_	_	DT	_	_	_	_	_
44	Src	_	_	NN	_	_	_	_	_
45	homology-2	_	_	NN	_	_	_	_	_
46	(	_	_	-LRB-	_	_	_	_	_
47	SH2	_	_	NN	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	domain	_	_	NN	_	_	_	_	_
50	that	_	_	WDT	_	_	_	_	_
51	triggers	_	_	VBZ	_	_	_	_	_
52	phosphorylation	_	_	NN	_	_	_	_	_
53	and	_	_	CC	_	_	_	_	_
54	dimerization	_	_	NN	_	_	_	_	_
55	after	_	_	IN	_	_	_	_	_
56	docking	_	_	VBG	_	_	_	_	_
57	to	_	_	TO	_	_	_	_	_
58	phosphorylated	_	_	VBN	_	_	_	_	_
59	receptors	_	_	NNS	_	_	_	_	_
60	and	_	_	CC	_	_	_	_	_
61	(	_	_	-LRB-	_	_	_	_	_
62	iv	_	_	NN	_	_	_	_	_
63	)	_	_	-RRB-	_	_	_	_	_
64	a	_	_	DT	_	_	_	_	_
65	C-terminal	_	_	JJ	_	_	_	_	_
66	transactivation	_	_	NN	_	_	_	_	_
67	domain	_	_	NN	_	_	_	_	_
68	with	_	_	IN	_	_	_	_	_
69	specific	_	_	JJ	_	_	_	_	_
70	tyrosine	_	_	NN	_	_	_	_	_
71	(	_	_	-LRB-	_	_	_	_	_
72	Y	_	_	NN	_	_	_	_	_
73	)	_	_	-RRB-	_	_	_	_	_
74	(	_	_	-LRB-	_	_	_	_	_
75	present	_	_	JJ	_	_	_	_	_
76	in	_	_	IN	_	_	_	_	_
77	all	_	_	DT	_	_	_	_	_
78	STATs	_	_	NNS	_	_	_	_	_
79	)	_	_	-RRB-	_	_	_	_	_
80	and	_	_	CC	_	_	_	_	_
81	serine	_	_	NN	_	_	_	_	_
82	(	_	_	-LRB-	_	_	_	_	_
83	S	_	_	NNP	_	_	_	_	_
84	)	_	_	-RRB-	_	_	_	_	_
85	residues	_	_	NNS	_	_	_	_	_
86	(	_	_	-LRB-	_	_	_	_	_
87	absent	_	_	JJ	_	_	_	_	_
88	in	_	_	IN	_	_	_	_	_
89	STAT2	_	_	NN	_	_	_	_	_
90	and	_	_	CC	_	_	_	_	_
91	6	_	_	CD	_	_	_	_	_
92	)	_	_	-RRB-	_	_	_	_	_
93	that	_	_	WDT	_	_	_	_	_
94	are	_	_	VBP	_	_	_	_	_
95	phosphorylated	_	_	VBN	_	_	_	_	_
96	upon	_	_	IN	_	_	_	_	_
97	transcriptional	_	_	JJ	_	_	_	_	_
98	activation	_	_	NN	_	_	_	_	_
99	.	_	_	.	_	_	_	_	_


1	Intensive	_	_	JJ	_	_	_	_	_
2	investigation	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	done	_	_	VBN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	STAT3	_	_	NNP	_	_	_	_	_
8	since	_	_	IN	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	discovery	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	revealing	_	_	VBG	_	_	_	_	_
13	its	_	_	PRP$	_	_	_	_	_
14	physiological	_	_	JJ	_	_	_	_	_
15	roles	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	early	_	_	JJ	_	_	_	_	_
18	embryonic	_	_	JJ	_	_	_	_	_
19	development	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	growth	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	differentiation	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	various	_	_	JJ	_	_	_	_	_
26	adult	_	_	JJ	_	_	_	_	_
27	tissues	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	its	_	_	PRP$	_	_	_	_	_
5	pathogenic	_	_	JJ	_	_	_	_	_
6	roles	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	cancer	_	_	NN	_	_	_	_	_
9	initiation	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	progression	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	metastasis	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	chemoresistance	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	immunoevasion	_	_	NN	_	_	_	_	_
18	have	_	_	VBP	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	uncovered	_	_	VBN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	STAT3	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	widely	_	_	RB	_	_	_	_	_
7	recognized	_	_	VBN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	oncogenic	_	_	JJ	_	_	_	_	_
11	factor	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	diverse	_	_	JJ	_	_	_	_	_
14	human	_	_	JJ	_	_	_	_	_
15	cancers	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	targeting	_	_	VBG	_	_	_	_	_
4	STAT3	_	_	NNP	_	_	_	_	_
5	might	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	attractive	_	_	JJ	_	_	_	_	_
9	therapeutic	_	_	JJ	_	_	_	_	_
10	strategy	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	HCC	_	_	NNP	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	review	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	summarize	_	_	VBP	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	oncogenic	_	_	JJ	_	_	_	_	_
9	roles	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	STAT3	_	_	NNP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	HCC	_	_	NNP	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	current	_	_	JJ	_	_	_	_	_
17	clinical	_	_	JJ	_	_	_	_	_
18	development	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	STAT3-targeted	_	_	JJ	_	_	_	_	_
21	therapeutics	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_

